Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
myeloid sarcoma as em blast crisis in bcr abl1 e6a2 cml with myelofibrosis and tb a case report
Original title: “Myeloid sarcoma as EM blast crisis in BCR-ABL1 e6a2+ CML with myelofibrosis and TB: a case report.”
Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
Original title: “Lilly scores early positive data for new JAK drug”
calreticulin type 26 mutation in myelofibrosis a rare variant with diagnostic challenges
Original title: “Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges.”
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
Original title: “Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road”
Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the company’s revenue.
Original title: “Karyopharm myeloma drug yields mixed data in myelofibrosis trial”
poiesis a phase iii study of add on navtemadlin in jak inhibitor na ve myelofibrosis patients with a suboptimal response to ruxolitinib
Original title: “POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.”
Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like myelofibrosis and the blood condition HHT.
Original title: “A startup making drugs for blood disorders banks $160M”
The announcement of the FDA’s ... therapy for MF. This regulatory milestone not only provides significant development incentives but also highlights the promising early clinical data from the zavabresib and ruxolitinib combination trial. For Opna Bio, this designation reinforces a commitment to addressing critical unmet needs in rare oncology through novel, targeted treatments... The announcement of the FDA’s Orphan Drug Designation for zavabresib underscores its potential as a transformative therapy for MF. This regulatory milestone not only provides significant development incentives but also highlights the promising early clinical data from the zavabresib and ruxolitinib combination trial. For Opna Bio, this designation reinforces a commitment to addressing critical unmet needs in rare oncology through novel, targeted treatments. The FDA granted Orphan Drug Designation to Opna Bio's zavabresib, a bromodomain and extra-terminal inhibitor, for treating myelofibrosis. “We believe that selective BET inhibition alongside JAK inhibition offers a promising new therapeutic approach for patients with myelofibrosis. We are further encouraged by recent positive meetings with the FDA to continue to test zavabresib in additional clinical studies,” Diaz concluded. This article originally appeared on Rare Disease Advisor ... Opna Bio announces orphan drug designation granted to OPN-2853 (zavabresib) for the treatment of myelofibrosis. This designation marks a significant regulatory milestone and underscores this promising treatment approach, emphasizing the unmet need for better therapies. MF is a rare, serious blood cancer involving bone marrow scarring that disrupts normal blood cell production, leading to anemia, fatigue, and splenomegaly. It affects around 25,000 people in the US. Current standard treatment often includes JAK inhibitors like ruxolitinib, but many patients eventually become resistant. Early evidence from an ongoing investigator-sponsored phase 1 trial (PROMise) combining zavabresib with ruxolitinib showed spleen length reduction of 50% or more in many patients previously unresponsive to ruxolitinib alone.
Original title: “FDA Grants Orphan Drug Status to Zavabresib for Myelofibrosis Therapy - Hematology Advisor”
Conditions: Polycythemia Vera; ET (Essential Thrombocythemia); Polycythemia Vera (PV); Essential Thrombocythemia (ET); Primary Myelofibrosis (MF); Primary Myelofibrosis (PMF); Myelofibrosis; Myelofibrosis (MF); Myelofibrosis, Primary; Myelofibrosis, Post ET; Myelofibrosis, Post PV; Myelofibrosis (PMF); Myelofibrosis，MF; Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera; My
Original title: “MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)”